We are currently enrolling treatment studies on Tourette Syndrome. We frequently develop new research studies and have created a Volunteer Research Registry to keep people updated on studies for which they might be eligible. If you would like to be contacted about new research studies, please complete the Volunteer Research Registry.
If you are interested in learning more about our studies and whether you might be eligible to participate in one, please contact us at:
1-877-501-TICS
CORDResearch@mgh.harvard.edu
Treatment studies
A Multicenter, Placebo-Controlled, Double-blind, Randomized, Parallel-Group, Phase 2b Study to Evaluate the Efficacy of Safety of Ecopipam Tablets in Children and Adolescent Subjects with Tourette’s Syndrome
PI: Dr. Daniel Geller, M.D.
Study Contact:
Hannah Smilansky
617-726-5527
Purpose of the study: We are studying ecopipam as a possible treatment option for Tourette syndrome (TS) in children and adolescents. Participants will be randomized to receive either ecopipam tablets or placebo for the duration of the study. After completing the randomized study, participants may have the option to enroll in the open-label extension study. If your child is 6-17 years old and is bothered by tics associated with TS, they may be eligible to participate.
Eligibility: Children and adolescents, 6 through 16 years of age, with Tourette syndrome
Length of the study: The overall study length is 14 weeks, including a 12-week treatment period and 2 week follow-up period. The study consists of about 8 visits to our clinic.
Visit type: Participation includes clinician-administered measures, safety assessments (such as blood draws, ECGs, and vital signs), and questionnaires for you and your child to complete. Your child would receive the study drug or placebo during the visits, and take it at home under the supervision of a parent or legal guardian.
Payment: You or your child will be paid up to $450 for your participation and will receive parking reimbursement.
